Fenofibrate and statins: CV outcomes in metabolic syndrome

Abundant evidence shows that lowering low-density lipoprotein (LDL) cholesterol concentrations with statins is the primary treatment option for minimising cardiovascular

What causes EPI?

The symptoms of EPI become most noticeable when production of lipase drops to 5%-10% of normal. When this happens, patients

SAD, a complex and silent signature of asthma

Small airways (internal diameter ≤2mm or internal perimeter of ≤6mm) are located beyond the 7th and 8th generation of the

The importance of treating acute pain

Acute pain alerts you to the fact the body has undergone some kind of injury, like a broken bone or

Amino acids and immunity

Immunoglobulins (antibodies) are proteins that fight antigens such as bacteria. Proteins require amino acids, which also enable vitamins and minerals

Bronchiectasis: What’s new in the management of this condition?

Treatment and prevention of acute exacerbations are with bronchodilators, clearance of secretions, antibiotics, and management of complications, such as haemoptysis

The role of demulcents and secretolytics in treating coughs

There is a global trend in both consumers and healthcare practitioners to opt for natural medication and cough syrups before

Pravastatin-fenofibrate combination therapy: Triglyceride-rich lipoproteins and residual risk on statins

Over the next 20 years the number of adults with diabetes is expected to rise with 20 % in developed

Atopic Dermatitis and Food Allergy – What does the research say

We have recorded the webinar event for you. In case you missed the live webinar, or in case you would

CPD webinar: Salt reduction & hypertension

Date: 5th May 2021 Time: 18h30 Topic: Salt reduction & hypertension. Presenter: Prof Brian Rayner Registration:  https://www.b2bcentral.co.za/webinar/salt-reduction-and-hypertension/ 

Colorectal cancer webinar

Date: 3 May 2021 Time: 6:00pm Topic: The Burden of Colorectal Cancer in the South African Landscape Presenter: Dr Leony

Multi-Matrix 5-ASA to induce remission in ulcerative colitis?

Action mechanism of mesalazine has not been established yet, but it is known that, besides inhibiting cyclooxygenase type 2, mesalazine